Still the moves are a notable step back for a company that launched two years ago with an approved cancer cell therapy a builtout drug pipeline and hundreds of millions of dollars. At the time Bluebird was struggling to turn research progress in cell and splitting the company as a better way forward with 2Seventy inheriting the companys oncology work and a resized Bluebird focusing on gene therapies for sickle cell disease and beta thalassemia